Ioannis Papaconstantinou1, Christos Zeglinas2, Maria Gazouli3, Konstantinos Nastos4, Anneza Yiallourou1, Panagis Lykoudis1, Konstantinos Evangelou3, Apostolos Papalois5, Marilena Papaioannou3, John Vlachogiannakos6, Charalampos Tzathas2. 1. Second Department of Surgery, Aretaieion Hospital, Medical School, University of Athens, Greece. 2. Department of Gastroenterology, Tzaneio General Hospital, Piraeus, Greece. 3. Molecular Carcinogenesis Group, Laboratory of Histology and Embryology, School of Medicine, University of Athens, Greece. 4. Second Department of Surgery, Aretaieion Hospital, Medical School, University of Athens, Greece. Electronic address: kosnastos@yahoo.gr. 5. Experimental-Research Center, ELPEN Pharmaceuticals, Pikermi, Attikis, Greece. 6. Second Department of Pathology, Laikon Hospital, University of Athens, Greece.
Abstract
BACKGROUND AND AIM: Infliximab is effective in the induction and maintenance of remission in Crohn's disease. Whether, the perioperative administration of anti-TNF-a compromises intestinal healing leading to anastomotic failure and increased risk of postoperative complications, remains controversial. The aim of the study was to evaluate the effect of Infliximab on intestinal anastomosis healing. METHODS: Fifty six wistar rats were divided into 4 groups: (a) 20 rats were subjected to excision of part of the terminal ileum followed by anastomosis which was evaluated on the 3rd or 7th postoperative day; (b) 20 rats received Infliximab and thereafter, the same surgical protocol as group (a) was followed; (c) 8 rats received Infliximab and served as relative control group; and (d) 8 served as absolute control group. Bursting pressure was used for testing intestinal healing. Additionally, the anastomoses were examined macroscopically, histologically and immunohistochemically for TGFb1, MMP1, MMP2 and Collagen V. The results were confirmed by Western blot analysis. RESULTS: There were no significant differences in bursting pressures and septic intra-abdominal events among non-Infliximab (a) and Infliximab-treated (b) groups. Infliximab-treated (b) group showed mild to moderate inflammation, whereas the non-Infliximab (a) group exhibited severe inflammation. Expression of TGFb1, MMP2 and collagen V was significantly higher in the Infliximab-treated (b) group. CONCLUSION: Infliximab seems to influence intestinal healing in terms of less inflammatory activity and higher tissue remodeling activity.
BACKGROUND AND AIM: Infliximab is effective in the induction and maintenance of remission in Crohn's disease. Whether, the perioperative administration of anti-TNF-a compromises intestinal healing leading to anastomotic failure and increased risk of postoperative complications, remains controversial. The aim of the study was to evaluate the effect of Infliximab on intestinal anastomosis healing. METHODS: Fifty six wistar rats were divided into 4 groups: (a) 20 rats were subjected to excision of part of the terminal ileum followed by anastomosis which was evaluated on the 3rd or 7th postoperative day; (b) 20 rats received Infliximab and thereafter, the same surgical protocol as group (a) was followed; (c) 8 rats received Infliximab and served as relative control group; and (d) 8 served as absolute control group. Bursting pressure was used for testing intestinal healing. Additionally, the anastomoses were examined macroscopically, histologically and immunohistochemically for TGFb1, MMP1, MMP2 and Collagen V. The results were confirmed by Western blot analysis. RESULTS: There were no significant differences in bursting pressures and septic intra-abdominal events among non-Infliximab (a) and Infliximab-treated (b) groups. Infliximab-treated (b) group showed mild to moderate inflammation, whereas the non-Infliximab (a) group exhibited severe inflammation. Expression of TGFb1, MMP2 and collagen V was significantly higher in the Infliximab-treated (b) group. CONCLUSION:Infliximab seems to influence intestinal healing in terms of less inflammatory activity and higher tissue remodeling activity.
Authors: Martin Rehn; Peter-Martin Krarup; Lise H Christensen; Jakob B Seidelin; Magnus S Ågren; Ingvar Syk Journal: Surg Infect (Larchmt) Date: 2015-07-14 Impact factor: 2.150
Authors: Paulo Gustavo Kotze; Mansur Paulo Saab; Bárbara Saab; Lorete Maria da Silva Kotze; Marcia Olandoski; Lilian Vital Pinheiro; Carlos Augusto Real Martinez; Maria de Lourdes Setsuko Ayrizono; Daniela de Oliveira Magro; Claudio Saddy Rodrigues Coy Journal: Dig Dis Sci Date: 2016-12-08 Impact factor: 3.199
Authors: Bruna Zini de Paula Freitas; Fábio Guilherme Campos; Danilo Toshio Kanno; Andress Godoy Delben; José Aires Pereira; Roberta Laís Dos Santos Mendonça; Carlos Augusto Real Martinez Journal: J Gastrointest Surg Date: 2021-09-24 Impact factor: 3.267